🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just out in NEJM : VERITAC-2 trial of oral PROTAC ER degrader vepdegestrant vs. fulvestrant in ER+/HER2– advanced BC ESR1-mut pts: - PFS 5.0 vs 2.1 mo - HR 0.58 (0.4–0.8) P<0.01 ITT: - PFS 3.8 vs 3.6 mo - HR 0.83 (0.69–1.0) P=0.07 G ≥3 AEs: 23.4% vs 17.6% OncoAlert #bcsm

Dr. Erica Mayer (Erica Mayer) will present results from the #TRADEstudy - a phase 2 trial assessing the tolerability of #abemaciclib dose escalation in early-stage HR+/HER2- #BreastCancer, in the #ASCO25 Rapid Oral Abstract Session on Sunday.

OS data from INAVO120 trial out in NEJM Inavolisib + palbo+fulv vs placebo combo in PIK3CA-mut HR+ MBC ‼️OS 34 vs 27 mo (HR 0.67, 0.5–0.9, P=0.02) PFS 17 vs 7 mo (HR 0.42) ORR 63 vs 28% (P<0.01) ⚠️ Discont due to AE 6.8% vs 0.6% ⬆️ hyperglycemia & mucositis OncoAlert

Data from Ph I/Ib trials - #Inavolisib in PIK3CA-mut HR+/HER2– mBC - 58% of pts prediabetic/obese ⚠️ 81% developed hyperglycemia (HG); 35% grade 3–4 - 86% resolved; 42% had dose interruptions Most common anti-HG meds: metformin (53%), SGLT2-i (26%), DPP4-i (23%) OncoAlert

ASCENT-04 presented by Sara Tolaney at #ASCO25 SG + pembro vs chemo + pembro in PD-L1+ adv TNBC PFS: HR 0.65 (0.51–0.84), P = .0009 ORR 59.7% vs 53.2% DOR 16.5 vs 9.2 mo G≥3 AEs 71% vs 70% Dose red: 35% vs 44% ‼️ New 1st line option for mTNBC! Dana-Farber’s Breast Oncology Center OncoAlert

The OncoAlert🚨 RoundUp DAY TWO #ASCO25 REGISTER HERE 👉 OncoAlert360.com OR buff.ly/p0O1gZ8 FOR A MORE COMPLETE VIEW of the TOP of DAY 2 of the congress Discussing:✅ ✅ASCENT-04/KEYNOTE #BreastCancer ✅VERITAC-2 in BreastCancer ✅INAVO120 in BreastCancer

Don’t miss Dr. Sara Tolaney's (Sara Tolaney) exciting presentation of the interim results from DESTINY-Breast09 at #ASCO25! 🗓️ Monday, June 2 ⏰ 7:30 AMCDT 📍 Hall D1

TRADE trial presented by Erica Mayer Adjuv abemaciclib w/ dose escalation in HR+ eBC - Primary endpoint met (29.2%) & 70.8% reached 150 mg BID at 12 wks - 93.3% still on tx at 12 wks ⬇️ discontinuation vs monarchE Early dose escalation may improve tolerability OncoAlert

DESTINY-Breast09 presented by Sara Tolaney at #ASCO25 T-DXd + P improved 1L outcomes in HER2+ mBC vs THP: mPFS (BICR): 40.7 vs 26.9 mo, HR: 0.56 (0.44–0.71), P<0.01 ORR: 85.1% vs 78.6% CR rate: 15.1% vs 8.5% mDOR: 39.2 vs 26.4 mo ⚠️ ILD 12.1% (Gr 5: 0.5%) OncoAlert

🚨 It’s poster session at #ASCO25: ICYI, please stop by poster board #50 to chat about the differential genomic landscape of ER-low vs ER+ and ER– metastatic #breastcancer. #bcsm Dana-Farber’s Breast Oncology Center Dana-Farber News Università degli Studi di Milano Link to the abstract: asco.org/abstracts-pres…

How does HER2+ ILC fare long-term? #ALTTO data ⬆️ CNS relapse risk in ILC vs NST (13.6% vs 5.0%; HR 3.14) – DFS & OS similar despite clinicopathologic differences – Importance of central histology review Poster BD135 | #ASCO25 – come by! OncoAlert

Happening Now! #ASCO25 Poster Session 👉Long-term outcomes of patients with HER2-positive invasive #LobularCarcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). Guilherme Nader Marta 📍Abs 542 | Poster Bd 135 | Jun 2, 9-12 PM CDT | Hall A

Happening Now! #ASCO25 Poster Session 👉 Use of baseline plasma circulating tumor DNA (#ctDNA) to predict duration of endocrine therapy and CDK4/6 inhibitor therapy and to analyze intrinsic vs acquired #EndocrineResistance. Pietro De Placido 📍Abs 1075 | Poster Bd 54 | Jun 2,

New in NEJM - OASIS-4 trial shows elinzanetant significantly ⬇️ vasomotor symptoms from ET in HR+ breast cancer - Week 4: −6.5 vs −3.0 episodes/day - Week 12: −7.8 vs −4.2 episodes/day - Well-tolerated overall Accompanied by an editorial from Ann Partridge MD, MPH OncoAlert

Agree, extremely relevant! Carmine Valenza

Even HP was not tolerable for me as maintenance treatment for HER2+ MBC. The patient community calls Perjeta “poo-jeta” for a reason! Indefinite T-DxD is not realistic- survivors will have to contend with long term SEs of ADCs (think ❤️& liver fx) #ASCO25 #bcsm

In patients who relapse after receiving adjuvant abemaciclib: Median duration of first-line treatment is only 3.0 months! The number of such patients will soon increase. Their prognosis after relapse is extremely poor. We must urgently develop more effective strategies!

x.com/i/article/1931…

ICYMI at #ASCO25: 1L SG + pembro significantly improves PFS compared w/ chemo + pembro in PD-L1–positive triple-negative #breastcancer; combo was associated w/ 35% reduction in risk of disease progression or death: brnw.ch/21wTiLO #ASCODailyNews